Neuropharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Retraction Notice to "Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis" [Neuropharmacology, 107 (2016) 432 - 450]
Neuropharmacology. 2024 Mar 4:109894. doi: 10.1016/j.neuropharm.2024.109894. Online ahead of print.NO ABSTRACTPMID:38443226 | DOI:10.1016/j.neuropharm.2024.109894 (Source: Neuropharmacology)
Source: Neuropharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Asmaa M Teema Sawsan A Zaitone Yasser M Moustafa Source Type: research

Quantitative T < sub > 2 < /sub > mapping-based longitudinal assessment of brain injury and therapeutic rescue in the rat following acute organophosphate intoxication
This study supports the utility of T2 mapping for longitudinally monitoring brain injury and highlights the therapeutic potential of ALLO as an adjunct therapy to mitigate chronic morbidity associated with acute OP intoxication.PMID:38437913 | DOI:10.1016/j.neuropharm.2024.109895 (Source: Neuropharmacology)
Source: Neuropharmacology - March 4, 2024 Category: Drugs & Pharmacology Authors: Alita Jesal D Almeida Brad A Hobson Naomi Saito Donald A Bruun Valerie A Porter Danielle J Harvey Joel R Garbow Abhijit J Chaudhari Pamela J Lein Source Type: research

The MCs - Cytokines axis in ASD
Neuropharmacology. 2024 Feb 29:109890. doi: 10.1016/j.neuropharm.2024.109890. Online ahead of print.ABSTRACTAutism Spectrum Disorder (ASD) is a neurodevelopmental disturbance, diagnosed in early childhood. It is associated with varying degrees of dysfunctional communication and social skills, repetitive and stereotypic behaviors. Regardless of the constant increase in the number of diagnosed patients, there are still no established treatment schemes in global practice. Many children with ASD have allergic symptoms, often in the absence of mast cell (MC) positive tests. Activation of MCs may release molecules related to inf...
Source: Neuropharmacology - March 2, 2024 Category: Drugs & Pharmacology Authors: Eleonora Kovacheva Maria Gevezova Michael Maes Victoria Sarafian Source Type: research

Retigabine and gabapentin restore channel function and neuronal firing in a cellular model of an epilepsy-associated dominant-negative KCNQ5 variant
Neuropharmacology. 2024 Feb 28:109892. doi: 10.1016/j.neuropharm.2024.109892. Online ahead of print.ABSTRACTKCNQ5 encodes the voltage-gated potassium channel KV7.5, a member of the KV7 channel family, which conducts the M-current. This current is a potent regulator of neuronal excitability by regulating membrane potential in the subthreshold range of action potentials and mediating the medium and slow afterhyperpolarization. Recently, we have identified five loss-of-function variants in KCNQ5 in patients with genetic generalized epilepsy. Using the most severe dominant-negative variant (R359C), we set out to investigate ph...
Source: Neuropharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Johanna Kr üger Holger Lerche Source Type: research

Exploring the therapeutic potential of cannabidiol for sleep deprivation-induced hyperalgesia
Neuropharmacology. 2024 Feb 28:109893. doi: 10.1016/j.neuropharm.2024.109893. Online ahead of print.ABSTRACTHyperalgesia resulting from sleep deprivation (SD) poses a significant a global public health challenge with limited treatment options. The nucleus accumbens (NAc) plays a crucial role in the modulation of pain and sleep, with its activity regulated by two distinct types of medium spiny neurons (MSNs) expressing dopamine 1 or dopamine 2 (D1-or D2) receptors (referred to as D1-MSNs and D2-MSNs, respectively). However, the specific involvement of the NAc in SD-induced hyperalgesia remains uncertain. Cannabidiol (CBD), ...
Source: Neuropharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Kangsheng Zhu Siruan Chen Xia Qin Wanjun Bai Jie Hao Xiaolei Xu Han Guo Hui Bai Zuxiao Yang Sheng Wang Zongmao Zhao Tengfei Ji Dezhi Kong Wei Zhang Source Type: research

Opioid modulation of prefrontal cortex cells and circuits
Neuropharmacology. 2024 Feb 27;248:109891. doi: 10.1016/j.neuropharm.2024.109891. Online ahead of print.ABSTRACTSeveral neurochemical systems converge in the prefrontal cortex (PFC) to regulate cognitive and motivated behaviors. A rich network of endogenous opioid peptides and receptors spans multiple PFC cell types and circuits, and this extensive opioid system has emerged as a key substrate underlying reward, motivation, affective behaviors, and adaptations to stress. Here, we review the current evidence for dysregulated cortical opioid signaling in the pathogenesis of psychiatric disorders. We begin by providing an intr...
Source: Neuropharmacology - February 28, 2024 Category: Drugs & Pharmacology Authors: Rebecca H Cole Khaled Moussawi Max E Joffe Source Type: research

Opioid modulation of prefrontal cortex cells and circuits
Neuropharmacology. 2024 Feb 26:109891. doi: 10.1016/j.neuropharm.2024.109891. Online ahead of print.ABSTRACTSeveral neurochemical systems converge in the prefrontal cortex (PFC) to regulate cognitive and motivated behaviors. A rich network of endogenous opioid peptides and receptors spans multiple PFC cell types and circuits, and this extensive opioid system has emerged as a key substrate underlying reward, motivation, affective behaviors, and adaptations to stress. Here, we review the current evidence for dysregulated cortical opioid signaling in the pathogenesis of psychiatric disorders. We begin by providing an introduc...
Source: Neuropharmacology - February 28, 2024 Category: Drugs & Pharmacology Authors: Rebecca H Cole Khaled Moussawi Max E Joffe Source Type: research

Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
In conclusion, although our data do not support the repurposing of lorcaserin, acamprosate or ganaxolone per se for LID, we demonstrate value of an in silico approach to identify candidate molecules which, in combination with an in vivo screen, can facilitate clinical development decisions. The present study adds to a growing literature in support of this paradigm shifting approach in the repurposing pipeline.PMID:38412888 | DOI:10.1016/j.neuropharm.2024.109880 (Source: Neuropharmacology)
Source: Neuropharmacology - February 27, 2024 Category: Drugs & Pharmacology Authors: Tom H Johnston Alix M B Lacoste Paula Ravenscroft Jin Su Sahar Tamadon Mahtab Seifi Anthony E Lang Susan H Fox Jonathan M Brotchie Naomi P Visanji Source Type: research